These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 8369102)

  • 1. Circadian secretion pattern of melatonin in de novo parkinsonian patients: evidence for phase-shifting properties of l-dopa.
    Fertl E; Auff E; Doppelbauer A; Waldhauser F
    J Neural Transm Park Dis Dement Sect; 1993; 5(3):227-34. PubMed ID: 8369102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circadian secretion pattern of melatonin in Parkinson's disease.
    Fertl E; Auff E; Doppelbauer A; Waldhauser F
    J Neural Transm Park Dis Dement Sect; 1991; 3(1):41-7. PubMed ID: 2064730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response to L-DOPA in multiple system atrophy.
    Parati EA; Fetoni V; Geminiani GC; Soliveri P; Giovannini P; Testa D; Genitrini S; Caraceni T; Girotti F
    Clin Neuropharmacol; 1993 Apr; 16(2):139-44. PubMed ID: 8477409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study of circadian melatonin secretion pattern at different stages of Parkinson's disease.
    Bordet R; Devos D; Brique S; Touitou Y; Guieu JD; Libersa C; Destée A
    Clin Neuropharmacol; 2003; 26(2):65-72. PubMed ID: 12671525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological basis of akinesia in Parkinson's disease.
    Narabayashi H
    J Neural Transm Suppl; 1983; 19():143-51. PubMed ID: 6583305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An analysis of long-term L-dopa therapy in 122 cases of Parkinson's disease over 14 years--when should L-dopa therapy be initiated?
    Indo T; Takahashi A
    Jpn J Med; 1986 May; 25(2):114-21. PubMed ID: 3747258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Benefit of L-DOPA-without-DCI (decarboxylase inhibitor) therapy on wearing-off phenomenon in advanced stages of Parkinson's disease patients].
    Hironishi M; Miwa H; Kondo T
    No To Shinkei; 2002 Feb; 54(2):127-32. PubMed ID: 11889758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early detection of L-dopa response in parkinsonian patients with a standardized tracking test.
    Albani C; Buck A
    Adv Neurol; 1993; 60():386-9. PubMed ID: 8420158
    [No Abstract]   [Full Text] [Related]  

  • 9. Early morning akinesia in Parkinson's disease: effect of standard carbidopa/levodopa and sustained-release carbidopa/levodopa.
    Pahwa R; Lyons K; McGuire D; Dubinsky R; Hubble JP; Koller WC
    Neurology; 1996 Apr; 46(4):1059-62. PubMed ID: 8780091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of parkinsonism with l-dopa and a decarboxylase inhibitor. An electrophysiological and clinical study.
    Dietrichson P; Presthus J; Holmsen R
    Eur Neurol; 1975; 13(4):339-49. PubMed ID: 1149754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pharmacokinetic profile of the "first ever" oral dose of levodopa in de novo patients with Parkinson's disease.
    Djaldetti R; Rosmarin V; Ziv I; Melamed E
    Clin Neuropharmacol; 2001; 24(2):95-8. PubMed ID: 11307044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [L-dopa, biperiden and sebum excretion in Parkinson disease].
    Villares JC
    Arq Neuropsiquiatr; 1989 Mar; 47(1):31-8. PubMed ID: 2764750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of melatonin on sleep disorders in a monkey model of Parkinson's disease.
    Belaid H; Adrien J; Karachi C; Hirsch EC; François C
    Sleep Med; 2015 Oct; 16(10):1245-51. PubMed ID: 26429753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolactin response as an index of dopaminergic receptor function in Parkinson's disease. Correlation with clinical findings and therapeutic response.
    Agnoli A; Baldassarre M; Ruggieri S; Falaschi P; Urso RD; Rocco A
    J Neural Transm; 1981; 51(1-2):123-34. PubMed ID: 7264625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
    Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
    Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. L-dopa therapy combined with peripheral decarboxylase inhibitor (MK-486) in Parkinsonism.
    Ohmoto T; Kishikawa H
    Folia Psychiatr Neurol Jpn; 1975; 29(1):1-12. PubMed ID: 1158313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dilemma in the treatment of Parkinson's disease with L-dopa.
    Kuno S
    Eur Neurol; 1994; 34 Suppl 3():17-9. PubMed ID: 7821330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Parkinsonian tremor, rigidity and flapping tremor].
    Kuno S
    Nihon Rinsho; 1993 Nov; 51(11):2823-8. PubMed ID: 8277556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences in the reduced 18F-Dopa uptakes of the caudate and the putamen in Parkinson's disease: correlations with the three main symptoms.
    Otsuka M; Ichiya Y; Kuwabara Y; Hosokawa S; Sasaki M; Yoshida T; Fukumura T; Masuda K; Kato M
    J Neurol Sci; 1996 Mar; 136(1-2):169-73. PubMed ID: 8815166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of L-Dopa on circadian rhythms of 6-OHDA striatal lesioned rats: a radiotelemetric study.
    Boulamery A; Simon N; Vidal J; Bruguerolle B
    Chronobiol Int; 2010 Jan; 27(2):251-64. PubMed ID: 20370468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.